The DNA Binding and Catalytic Domains of Poly(ADP-ribose) Polymerase 1 Cooperate in the Regulation of Chromatin Structure and Transcription
Overview
Affiliations
We explored the mechanisms of chromatin compaction and transcriptional regulation by poly(ADP-ribose) polymerase 1 (PARP-1), a nucleosome-binding protein with an NAD(+)-dependent enzymatic activity. By using atomic force microscopy and a complementary set of biochemical assays with reconstituted chromatin, we showed that PARP-1 promotes the localized compaction of chromatin into supranucleosomal structures in a manner independent of the amino-terminal tails of core histones. In addition, we defined the domains of PARP-1 required for nucleosome binding, chromatin compaction, and transcriptional repression. Our results indicate that the DNA binding domain (DBD) of PARP-1 is necessary and sufficient for binding to nucleosomes, yet the DBD alone is unable to promote chromatin compaction and only partially represses RNA polymerase II-dependent transcription in an in vitro assay with chromatin templates (approximately 50% of the repression observed with wild-type PARP-1). Furthermore, our results show that the catalytic domain of PARP-1, which does not bind nucleosomes on its own, cooperates with the DBD to promote chromatin compaction and efficient transcriptional repression in a manner independent of its enzymatic activity. Collectively, our results have revealed a novel function for the catalytic domain in chromatin compaction. In addition, they show that the DBD and catalytic domain cooperate to regulate chromatin structure and chromatin-dependent transcription, providing mechanistic insights into how these domains contribute to the chromatin-dependent functions of PARP-1.
Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia.
Bian X, Liu W, Yang K, Sun C Front Pharmacol. 2024; 15:1421816.
PMID: 39175540 PMC: 11338796. DOI: 10.3389/fphar.2024.1421816.
PARP1 as an Epigenetic Modulator: Implications for the Regulation of Host-Viral Dynamics.
Sobotka A, Tempera I Pathogens. 2024; 13(2).
PMID: 38392869 PMC: 10891851. DOI: 10.3390/pathogens13020131.
ADP-ribosylation from molecular mechanisms to therapeutic implications.
Suskiewicz M, Prokhorova E, Rack J, Ahel I Cell. 2023; 186(21):4475-4495.
PMID: 37832523 PMC: 10789625. DOI: 10.1016/j.cell.2023.08.030.
Sun X, Bai C, Li H, Xie D, Chen S, Han Y Mol Ther. 2023; 31(9):2633-2650.
PMID: 37482682 PMC: 10492194. DOI: 10.1016/j.ymthe.2023.07.018.
Cooperative targeting of PARP-1 domains to regulate metabolic and developmental genes.
Bamgbose G, Johnson S, Tulin A Front Endocrinol (Lausanne). 2023; 14:1152570.
PMID: 37347109 PMC: 10281051. DOI: 10.3389/fendo.2023.1152570.